Kadmon Holdings, Inc. (KDMN) News
Filter KDMN News Items
KDMN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KDMN News Highlights
- KDMN's 30 day story count now stands at 5.
- Over the past 21 days, the trend for KDMN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- LAW, ADTN and DWAC are the most mentioned tickers in articles about KDMN.
Latest KDMN News From Around the Web
Below are the latest news stories about Kadmon Holdings Inc that investors may wish to consider to help them evaluate KDMN as an investment opportunity.
Is Kadmon Holdings, Inc. (KDMN) A Good Stock To Buy?The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 873 world-class investment firms that we track and now have access to the collective wisdom contained in […] |
38 Stocks Moving In Thursday's Mid-Day SessionGainers Digital World Acquisition Corp. (NASDAQ: DWAC) shares jumped 132.3% to $23.14 following an announcement the company will merge with Trump Media & Technology Group. Portillo's Inc. (NASDAQ: PTLO) gained 45.9% to $29.18 after the company priced its IPO at $20 per share. TriState Capital Holdings, Inc. (NASDAQ: TSC) shares jumped 32.1% to $30.06 after Raymond James Financial announced it will acquire the company. TriState Capital announced better-than-expected Q3 earnings. China Finance Onl |
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates TGP, ESBK, KDMN, VNE; Shareholders are Encouraged to Contact the FirmNEW YORK, NY / ACCESSWIRE / October 8, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:Teekay LNG Partners L. (NYSE:TGP)concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Stonepeak for $17. |
SHAREHOLDER ALERT: WeissLaw LLP Reminds XLRN, JMP, ECHO, and KDMN Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates XLRN, ADTN, DSPG, KDMN; Shareholders are Encouraged to Contact the FirmNEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Acceleron Pharma Inc. (NASDAQ: XLRN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Merck & Co., Inc. for $180.00 per share in cash. If you are an Acceleron shareholder, click here to learn more about your rights and options. ADTRAN, Inc. (NASDAQ: ADTN) concerning potenti |
Kadmon Holdings, Inc.: Kadmon Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer''s 36th Annual MeetingNEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion |
Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of Kadmon, Echo Global, GreenSky, and Great Western Bancorp on behalf of Stockholders and Encourages Investors to Contact the FirmNEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of Kadmon Holdings, Inc. (NASDAQ: KDMN), Echo Global Logistics, Inc. (NASDAQ: ECHO), GreenSky, Inc. (NASDAQ: GSKY), and Great Western Bancorp, Inc. (NYSE: GWB). Additional information about each potential action can be found at the link provided. |
Kadmon Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual MeetingNEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors, in addition to other IL-15 preclinical work, at the Society for Immunotherapy of Cancer's (SITC 2021) 36th Annual Meeting, taking place virtually November 10 - 14, 2021. |
SHAREHOLDER ALERT: WeissLaw LLP Reminds CXP, JMP, ECHO, and KDMN Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
Verso, Kadmon Holdings See Activist ActionAtlas Capital entered a confidentiality agreement with coated-paper producer Verso. Magnetar Capital disclosed a large stake in biopharmaceutical firm Kadmon Holdings. |